Middle ear adenomatous neuroendocrine tumors: a 25-year experience at MD Anderson Cancer Center

Neuroendocrine tumors are extremely rare in the middle ear. We reviewed our institutional experience with middle ear adenomatous neuroendocrine tumors (MEANTs). We searched our institution’s pathology files to identify patients treated from 1990 to 2015 who had lesions classified as middle ear adeno...

Full description

Saved in:
Bibliographic Details
Published in:Virchows Archiv : an international journal of pathology 2017-11, Vol.471 (5), p.667-672
Main Authors: Bell, Diana, El-Naggar, Adel K., Gidley, Paul W.
Format: Article
Language:English
Subjects:
Adult
Aged
Brief Report
Cancer
Carcinoma
Differential diagnosis
Ear Neoplasms - pathology
Ear, Middle - pathology
Female
Humans
Lesions
Lymph nodes
Male
Medicine
Medicine & Public Health
Metastases
Middle Aged
Middle ear
Neoplasms
Neuroendocrine tumors
Neuroendocrine Tumors - pathology
Pathology
Patients
Quality
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Neuroendocrine tumors are extremely rare in the middle ear. We reviewed our institutional experience with middle ear adenomatous neuroendocrine tumors (MEANTs). We searched our institution’s pathology files to identify patients treated from 1990 to 2015 who had lesions classified as middle ear adenomas, adenomatous tumors, adenomatous tumors with neuroendocrine differentiation, carcinoid tumors of the middle ear, low-grade neuroendocrine tumors of the middle ear, and neuroendocrine carcinomas of the middle ear and identified 14 such patients for whom follow-up information was available. Herein, we review the pathology and differential diagnosis of these patients’ tumors and discuss the management and follow-up of these patients. Our report adds to the series cases of MEANTs with recurrences, lymph node involvement, distant metastases, and tumor-related deaths. Our experience suggests that, although these tumors have long been considered to be low-aggression neoplasms, long-term follow-up studies to ascertain this supposed benignity are warranted.
ISSN:0945-6317
1432-2307
DOI:10.1007/s00428-017-2155-6